AUTHORS
Matthew Lei, PharmD, Steven W. Champaloux, PhD, MPH2, Meng Wang, MPH, PhD3, Amy Hillsman, MSN, ANP-BC4, Rushir Choksi, MD5, Jonathon B. Cohen, MD, MS6, Mike Gart, MBA7, Brandon Wang, MBA8, Prateesh Varughese, PharmD, MBA9, Jeffrey Scott, MD10, Jing-Zhou Hou, MD, PhD11
AFFILIATIONS
1 Massachusetts General Hospital, Boston, Massachusetts, United States
2 IntegraConnect, West Palm Beach, Florida, United States
3 IntegraConnect, West Palm Beach, Florida, United States
4 IntegraConnect, West Palm Beach, Florida, United States
5 University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
6 Emory Winship Cancer Institute, Atlanta, Georgia, United States
7 IntegraConnect, West Palm Beach, Florida, United States
8 IntegraConnect, West Palm Beach, Florida, United States
9 IntegraConnect, West Palm Beach, Florida, United States
10 IntegraConnect, West Palm Beach, Florida, United States
11 University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
ABSTRACT
Background: Despite increasing utilization of chimeric antigen receptor T-cell (CAR-T) therapy for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), a subset of patients who may be eligible for CAR-T continue through multiple subsequent lines of therapy without receiving cellular therapy. Characterizing patients who receive CAR-T versus those who continue through multiple documented non-CAR-T treatment lines may help identify barriers to utilization, inform care delivery models and optimize referral timing for eligible patients.
Methods: Patients with R/R DLBCL aged <80 years who initiated second (2L) or third-line (3L) therapy between January 2022 and March 2026 were identified from a large integrated community oncology practice within IntegraConnect's PrecisionQ deidentified database. The community oncology clinic serves as the primary point of oncology care, with integrated longitudinal Electronic Health Record data capturing treatment delivery and follow-up across affiliated outpatient clinics and inpatient hospital settings, including CAR-T therapy. Patients were categorized by CAR-T treatment status, and utilization was evaluated annually. To better characterize patients who did not receive CAR-T therapy, we examined a subgroup of patients with ≥3 documented non-CAR-T lines of therapy. This approach was used because CAR-T administered outside the network may not have been captured, whereas patients continuing through multiple documented non-CAR-T treatment lines were more likely to represent patients who did not receive CAR-T therapy. Patient characteristics, including age, ECOG performance status, International Prognostic Index (IPI) risk group, Charlson Comorbidity Index (CCI), payer distribution, and line-of-therapy distribution, were summarized descriptively.
Results: Among 584 patients aged <80 years who initiated 2L or 3L therapy between 2022 and March 2026, 182 received CAR-T therapy and 402 did not receive CAR-T therapy. The median age of CAR-T recipients was 65.5 years (interquartile range [IQR], 55.0-72.0), 95.4% were White, and 63.7% were male. The median age of CAR-T recipients increased over time, suggesting broader utilization among older patients. Axicabtagene ciloleucel accounted for 64.3% (117/182) of CAR-T therapies administered, while liscocabtagene maraleucel comprised 35.7% (65/182). CAR-T was most frequently administered in the 2L setting (122/182; 67.0%). When examining patients who either 1) received CAR-T therapy (n=182) or 2) had ≥3 documented non-CAR-T lines of therapy (n=136), overall utilization for CAR-T increased from 46.9% in 2022 to 54.7% in 2023, 49.4% in 2024, and 71.6% in 2025. CAR-T recipients were younger than patients in the non-CAR-T comparator subgroup (median age, CAR-T: 65.5 vs non-CAR-T: 68.0 years; p<0.01).
In 2025, more patients received CAR-T than were identified in the non-CAR-T subgroup with ≥3 documented lines of therapy (CAR-T: n=48 vs non-CAR-T: n=19). Compared with CAR-T recipients, patients in the non-CAR-T subgroup were older, with a higher proportion aged ≥65 years (CAR-T: 62.5% vs non-CAR-T: 78.9%), ≥70 years (CAR-T: 43.8% vs non-CAR-T: 47.4%), and ≥75 years (CAR-T: 20.8% vs non-CAR-T: 36.8%). Race/ethnicity, ECOG performance status, IPI risk category, Charlson Comorbidity Index, and insurance coverage were broadly similar between groups. Commercial coverage was comparable between groups (CAR-T: 20.6% vs non-CAR-T: 21.4%), as well as Medicare/Medicaid coverage (CAR-T: 64.7% vs non-CAR-T: 71.4%).
Conclusion: CAR-T utilization within an integrated oncology practice increased from 46.9% in 2022 to 71.6% in 2025, suggesting improved uptake among patients who may be eligible for cellular therapy. Age was the primary distinguishing characteristic among patients who continued through multiple subsequent non-CAR-T lines of therapy, whereas disease risk, performance status, comorbidity burden, and treatment characteristics were otherwise comparable. While limited by small sample size, these findings support further investigation of referral pathways, treatment access, insurance dynamics, and other factors that may influence CAR-T utilization.
DISCLOSURES
Matthew Lei, PharmD: MJH Life Sciences - Honoraria; Johnson and Johnson - Research Funding; Genentech - Consultancy (Includes expert testimony); MJH Life Sciences - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); IntegraConnect - Consultancy (Includes expert testimony); Center for Business Models - Consultancy (Includes expert testimony); Eli Lilly - Consultancy (Includes expert testimony); C4XD - Consultancy (Includes expert testimony); Replimune - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony)